Table 1.
Echocardiographic indices in the various mice groups studied
| Group | IVS (mm) | LVID (mm) | LVPW (mm) | HR (b.p.m.) | FS (%) | LV mass/BW (mg/g) | Age (days) |
|---|---|---|---|---|---|---|---|
| Young | 0.62 ± 0.03 | 4.29 ± 0.09 | 0.65 ± 0.02 | 442.5 ± 7.6 | 28.8 ± 1.3 | 3.31 ± 0.18 | 118.1 ± 3.6 |
| Young + I | 0.60 ± 0.04 | 4.47 ± 0.09 | 0.58 ± 0.02* | 449.5 ± 8.0 | 28.2 ± 1.4 | 3.13 ± 0.19* | 142.2 ± 3.8 |
| G4+/− | 0.76 ± 0.01 | 4.29 ± 0.05 | 0.70 ± 0.04 | 428.0 ± 34.0 | 29.5 ± 2.2 | 2.80 ± 0.10 | 145.0 ± 0.0 |
| G4+/− + I | 0.70 ± 0.04** | 4.46 ± 0.16 | 0.63 ± 0.02* | 396.0 ± 27.0 | 28.6 ± 2.4 | 2.60 ± 0.20** | 167.0 ± 11.0 |
| Bcl-2 | 0.61 ± 0.05 | 4.00 ± 0.15 | 0.66 ± 0.04 | 432.0 ± 5.0 | 30.2 ± 2.9 | 3.10 ± 0.00 | 122.0 ± 5.0 |
| Bcl-2 + I | 0.65 ± 0.03 | 3.94 ± 0.09 | 0.63 ± 0.03 | 441.0 ± 11.0 | 30.9 ± 0.9 | 3.10 ± 0.20 | 122.0 ± 5.0 |
| Old | 0.75 ± 0.06 | 4.40 ± 0.13 | 0.78 ± 0.07 | 484.0 ± 15.1 | 30.0 ± 0.8 | 3.41 ± 0.41 | 449.8 ± 14.9 |
| Old + I | 0.69 ± 0.03 | 4.63 ± 0.09* | 0.70 ± 0.06 | 453.2 ± 18.1 | 21.3 ± 0.8* | 3.18 ± 0.23 | 480.1 ± 15.1 |
| Old G4+/− | 0.79 ± 0.06 | 4.11 ± 0.19 | 1.01 ± 0.18 | 409.0 ± 29.0 | 24.3 ± 3.8 | 3.60 ± 0.80 | 441.0 ± 2.0 |
| Old G4+/− + I | 0.77 ± 0.06 | 5.33 ± 0.52* | 0.78 ± 0.12 | 422.0 ± 20.0 | 17.8 ± 2.6*,** | 5.00 ± 1.50 | 441.0 ± 1.0 |
BW, body weight; FS, fractional shortening; G4, GATA4; HR, heart rate; I, imatinib; IVS, interventricular septum (diastole); LVID, left ventricular interdimension (diastole); LVPW, left ventricular posterior wall (diastole).
Two-way analysis of variance was used to test significance with the genotype as the first variable and treatment as the second variable.
*Significance of treatment (P < 0.05);
**significance of genotype (P < 0.05).
Imatinib mesylate cardiotoxicity
WMaharsy et al.